Duloxetine Capsule, Delayed Release
Product Images NDC 68001-595

19 FDA label images from Bluepoint Laboratories · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 19 technical images submitted to the FDA as part of the official labeling for Duloxetine (NDC 68001-595). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bluepoint Laboratories, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Structure (Duloxetine Structure)

Structure (Duloxetine Structure)
Chemical structure diagram of Duloxetine hydrochloride, showing the molecular connectivity including a naphthalene moiety, a thiophene ring, and an amine group with attached hydrochloride.*
FDA Label Image

Figure1 (Duloxetine Fig1)

Figure1 (Duloxetine Fig1)
A Kaplan-Meier curve charting the proportion of patients with relapse over time in days from randomization for Duloxetine compared to placebo. The graph shows relapse proportions on the vertical axis and time to relapse in days on the horizontal axis, with a line for Duloxetine and a separate line for placebo.*
FDA Label Image

Figure2 (Duloxetine Fig2)

Figure2 (Duloxetine Fig2)
A survival curve graph depicting the proportion of patients with relapse over time from randomization to relapse in days. The graph compares two treatments: placebo (dashed line) and duloxetine (solid line), showing a lower proportion of relapse in patients treated with duloxetine over approximately 250 days.*
FDA Label Image

Figure3 (Duloxetine Fig3)

Figure3 (Duloxetine Fig3)
A line graph showing the percentage of patients improved versus percent improvement in pain from baseline. The graph compares Duloxetine 60 mg BID, Duloxetine 60 mg QD, Duloxetine 20 mg QD, and placebo. Each treatment group is represented by a distinct line, showing trends in patient improvement across increasing pain relief percentages.*
FDA Label Image

Figure4 (Duloxetine Fig4)

Figure4 (Duloxetine Fig4)
A line graph comparing the percentage of patients improved at different levels of percent improvement in pain from baseline for Duloxetine 60 mg BID, Duloxetine 60 mg QD, and placebo. The vertical axis shows the percentage of patients improved, and the horizontal axis shows percent improvement in pain from baseline.*
FDA Label Image

Figure5 (Duloxetine Fig5)

Figure5 (Duloxetine Fig5)
A line graph showing the percentage of patients improved versus percent improvement in pain from baseline. It compares three groups: Duloxetine 60 mg twice daily, Duloxetine 60 mg once daily, and placebo, illustrating the relationship between pain improvement and patient response rates over different thresholds of pain improvement.*
FDA Label Image

Figure6 (Duloxetine Fig6)

Figure6 (Duloxetine Fig6)
A line graph showing the percentage of patients improved versus percent improvement in pain from baseline. It compares Duloxetine capsules at 20 mg, 60 mg, and 120 mg once daily doses with a placebo, illustrating patient response rates across varying levels of pain improvement.*
FDA Label Image

Figure7 (Figure 7)

Figure7 (Figure 7)
A line graph comparing the percentage of patients improved versus percent improvement in pain from baseline. It shows two lines: one for Duloxetine 60 mg once daily and another for placebo, indicating patient improvement percentages at various pain improvement thresholds.*
FDA Label Image

Figure8 (Duloxetine Fig8)

Figure8 (Duloxetine Fig8)
A line graph comparing the percentage of patients improved by percent improvement in pain from baseline (BOCF) between Duloxetine 60/120 mg once daily and placebo groups. The x-axis shows percent improvement in pain from 0 to 100, and the y-axis shows the percentage of patients improved up to 100%. The graph displays two trend lines representing the treatment and placebo responses.*
FDA Label Image

Figure9 (Duloxetine Fig9)

Figure9 (Duloxetine Fig9)
A line graph comparing the percentage of patients improved versus percent improvement in pain from baseline (BOCF) between placebo and Duloxetine 60 mg once daily. The x-axis shows percent improvement in pain from 0 to 100, and the y-axis shows the percentage of patients improved from 0 to 100%, with two vertical dashed lines at 30% and 50% improvement.*
FDA Label Image

Figure10 (Duloxetine Fig10)

Figure10 (Duloxetine Fig10)
A line graph comparing the percentage of patients improved versus the percent improvement in pain from baseline (BOCF) for Duloxetine 60/120 mg once daily and placebo. The x-axis displays ranges of percent pain improvement, and the y-axis shows the percentage of patients improved. Duloxetine is represented with a solid line and placebo with a dashed line.*
FDA Label Image

20mg Bharuch (Dulox Dr Caps 20mg (60ct) Bharuch Site Rev 0325)

20mg Bharuch (Dulox Dr Caps 20mg (60ct) Bharuch Site Rev 0325)
Packaging label for Duloxetine delayed-release capsules, 20 mg strength, by BluePoint Laboratories. The label includes the product name, dosage form, strength, quantity of 60 capsules, and manufacturer information. It features a barcode, NDC number 68001-594-06, and usage instructions emphasizing dispensing the accompanying medication guide.*
FDA Label Image

20mg Paithan (Dulox Dr Caps 20mg (60ct) Paithan Site Rev 0325)

20mg Paithan (Dulox Dr Caps 20mg (60ct) Paithan Site Rev 0325)
Label for Duloxetine Delayed-Release Capsules 20 mg by BluePoint Laboratories, containing 60 capsules. The label includes dosing instructions, storage conditions, manufacturer details (Ajanta Pharma Limited, India), and a barcode. It features the BluePoint Laboratories logo and states 'Rx Only.'*
FDA Label Image

30mg Bharuch (Dulox Dr Caps 30mg (30ct) Bharuch Site Rev 0325)

30mg Bharuch (Dulox Dr Caps 30mg (30ct) Bharuch Site Rev 0325)
Duloxetine Delayed-Release Capsules 30 mg label from BluePoint Laboratories. The label includes dosage and storage information, NDC 68001-595-04, and states it contains 30 capsules. It is marked Rx Only with directions to dispense the accompanying Medication Guide. Manufacturer is Ajanta Pharma Limited, India.*
FDA Label Image

30mg Paithan (Dulox Dr Caps 30mg (30ct) Paithan Site Rev 0325)

30mg Paithan (Dulox Dr Caps 30mg (30ct) Paithan Site Rev 0325)
Label for Duloxetine Delayed-Release Capsules, 30 mg, by BluePoint Laboratories. The label shows dosage form and strength, manufacturer information, and a 30-capsule count. It includes storage instructions, USP assay note, and a barcode with NDC 68001-595-04. The label states the product is prescription only and manufactured by Ajanta Pharma Limited in India.*
FDA Label Image

40mg Bharuch (Dulox Dr Caps 40mg (30ct) Bharuch Site Rev 0325)

40mg Bharuch (Dulox Dr Caps 40mg (30ct) Bharuch Site Rev 0325)
Label for Duloxetine 40 mg delayed-release oral capsules by BluePoint Laboratories. The label states the strength (40 mg) and package contains 30 capsules. It includes instructions for pharmacists to dispense a Medication Guide and provides storage information and manufacturer details. A barcode and NDC number 68001-570-04 are visible.*
FDA Label Image

40mg Paithan (Dulox Dr Caps 40mg (30ct) Paithan Site Rev 0325)

40mg Paithan (Dulox Dr Caps 40mg (30ct) Paithan Site Rev 0325)
Duloxetine Delayed-Release Capsules 40 mg label from BluePoint Laboratories. The label states each capsule contains enteric-coated pellets equivalent to 40 mg Duloxetine. It includes the NDC 68001-570-04, directions to dispense the Medication Guide, and a package count of 30 capsules. The label also features storage and handling instructions and manufacturing details by Ajanta Pharma Limited, India.*
FDA Label Image

60mg Bharuch (Dulox Dr Caps 60mg (30ct) Bharuch Site Rev 0325)

60mg Bharuch (Dulox Dr Caps 60mg (30ct) Bharuch Site Rev 0325)
Duloxetine Delayed-Release Capsules 60 mg packaging label by BluePoint Laboratories. The label includes the strength, route (oral), 30 capsules count, and instructions to dispense the accompanying Medication Guide. Manufacturer details and storage conditions appear on the left side, along with the NDC 68001-596-04 and barcode.*
FDA Label Image

60mg (Dulox Dr Caps 60mg (30ct) Paithan Site Rev 0325)

60mg (Dulox Dr Caps 60mg (30ct) Paithan Site Rev 0325)
Duloxetine Delayed-Release 60 mg capsules label by BluePoint Laboratories. The label includes dosage form and strength, manufacturer information (Ajanta Pharma Limited, India), barcode, and a 30-count package size. It also notes the product is Rx only and includes storage and usage instructions.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.